A detailed history of National Bank Of Canada transactions in Protalix Bio Therapeutics, Inc. stock. As of the latest transaction made, National Bank Of Canada holds 6,000 shares of PLX stock, worth $11,280. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,000
Previous 6,000 -0.0%
Holding current value
$11,280
Previous $6,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$0.9 - $1.17 $90 - $117
-100 Reduced 1.64%
6,000 $6,000
Q4 2023

Feb 06, 2024

SELL
$1.34 - $1.85 $37,386 - $51,615
-27,900 Reduced 82.06%
6,100 $10,000
Q3 2023

Oct 10, 2023

SELL
$1.49 - $2.02 $402,002 - $544,996
-269,800 Reduced 88.81%
34,000 $56,000
Q2 2023

Jul 26, 2023

BUY
$2.0 - $3.36 $595,400 - $1 Million
297,700 Added 4880.33%
303,800 $607,000
Q1 2022

May 05, 2022

BUY
$0.81 - $1.17 $81 - $117
100 Added 1.67%
6,100 $6,000
Q4 2021

Jan 24, 2022

BUY
$0.81 - $1.33 $4,860 - $7,980
6,000 New
6,000 $5,000

Others Institutions Holding PLX

About Protalix BioTherapeutics, Inc.


  • Ticker PLX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,753,400
  • Market Cap $93.5M
  • Description
  • Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso fo...
More about PLX
Track This Portfolio

Track National Bank Of Canada Portfolio

Follow National Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of National Bank Of Canada , based on Form 13F filings with the SEC.

News

Stay updated on National Bank Of Canada with notifications on news.